FDA Clears New Breast Implant Natrelle Inspira SoftTouch

The US Food and Drug Administration (FDA) today approved a new breast implant for women undergoing breast reconstruction, augmentation, or revision surgery, according to the device manufacturer.

The Natrelle Inspira SoftTouch (Allergan Pic) breast implant is a medium firmness cohesive silicone gel implant. The Natrelle line of breast implants now includes implants with three levels of cohesive gel, the company explained in a news release.

The Inspira line of breast implants “helps physicians to better meet diverse, patient-specific needs based on available breast tissue and desired outcomes,” David Nicholson, Allergan’s chief research and development officer, said in the release.

Natrelle breast implants are approved for breast reconstruction, including primary reconstruction to replace breast tissue that has been removed because of cancer or trauma or that has failed to develop properly because of a severe breast abnormality, as well as revision surgery to correct or improve the result of a primary breast reconstruction surgery.

Natrelle breast implants are also approved for breast augmentation for women at least 22 years old for silicone-filled implants and for women at least 18 years old for saline-filled implants. Breast augmentation includes primary breast augmentation to increase breast size and revision surgery to correct or improve the result of a primary breast augmentation surgery. For more information, please visit the link below: